Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Prospective Intestinal Ultrasound Study for Artificial Intelligence Algorithm Development (PSIUSAD)

9 сентября 2026 г. обновлено: Matthew Smyth, University of British Columbia

Prospective Study for Intestinal Ultrasound Algorithm Development

This observational study will use intestinal ultrasound images to help develop computer programs that may make it easier to assess bowel inflammation.

The study will include adults who are healthy or who are having an intestinal ultrasound as part of care for inflammatory bowel disease, such as Crohn disease or ulcerative colitis. Researchers want to find out whether a computer program can measure bowel wall thickness from ultrasound images as accurately as experienced ultrasound clinicians. They will also explore whether the program can identify other changes in the bowel.

Participants will have an intestinal ultrasound as part of their usual care. People who agree to take part will allow the research team to use de-identified ultrasound images and a small amount of related health information. No medication, experimental treatment, or additional ultrasound procedure will be given for this study. The computer program will not be used to make decisions about a participant's care, and participants will not receive individual results from the program.

Обзор исследования

Статус

Еще не набирают

Подробное описание

Inflammatory bowel disease, including Crohn disease and ulcerative colitis, requires reliable assessment of intestinal inflammation to support clinical monitoring and treatment decisions. Intestinal ultrasound is a non-invasive, point-of-care imaging method that can assess bowel inflammation without radiation exposure. However, its interpretation may vary by operator experience and local scanning practice.

This prospective, multicentre, observational study will collect de-identified intestinal ultrasound images, cine loops, and limited associated metadata from adults aged 18 years and older. Eligible participants may be healthy individuals with no known inflammatory bowel disease or individuals undergoing intestinal ultrasound for inflammatory bowel disease screening, monitoring, or another clinical reason. Intestinal ultrasound examinations will be performed as part of routine clinical care. The study does not add a treatment intervention, investigational drug, experimental device, or clinically directed diagnostic procedure.

Following informed consent, ultrasound images and cine loops generated during the routine examination will be exported in de-identified DICOM format. Limited information relevant to artificial intelligence development and validation, such as age, sex, self-reported race, pregnancy status, eligibility confirmation, and relevant scan-related or pre-existing clinical information, may also be recorded. Direct personal identifiers and personal health information will be removed before the data are transferred outside the clinical site.

The de-identified data will be reviewed for appropriate de-identification and formatting before secure transfer to Dova Health Intelligence Inc. The data will be annotated and used to develop, train, tune, and test computer vision algorithms designed to identify bowel structures and measure bowel wall thickness on intestinal ultrasound. The study will also assess the feasibility of developing algorithms to evaluate bowel wall layer stratification, luminal diameter, bowel wall flow, bowel wall scarring, gastrointestinal motility, and mesenteric fat proliferation.

The primary objective is to evaluate whether the computer vision algorithm prototype can measure bowel wall thickness with performance comparable to manual measurements by experienced sonographers. Secondary objectives include evaluating the quality, diversity, and usability of the collected ultrasound data for artificial intelligence development and assessing the feasibility of measuring additional intestinal ultrasound features.

The algorithms developed in this study are investigational and will not be used in routine clinical care during the study. No participant-level algorithm findings will be returned to participants, and participation is not expected to provide a direct clinical benefit. The primary foreseeable risk is a loss of confidentiality; this risk is mitigated through de-identification at the study site, verification of de-identification before transfer, secure file transfer, controlled access, and secure cloud-based storage. The study plans to enroll up to 95 participants internationally, including up to 30 participants at the British Columbia site.

Тип исследования

Наблюдательный

Регистрация (Оцененный)

95

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Контакты исследования

  • Имя: Cristian A Massaro, MSc
  • Номер телефона: 587-223-5248
  • Электронная почта: iusresearch@ibdcentrebc.ca

Места учебы

    • British Columbia
      • Vancouver, British Columbia, Канада, V6Z 2L2
        • IBD Centre of BC
        • Контакт:
        • Главный следователь:
          • Matthew J Smyth, MD

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

  • Взрослый
  • Пожилой взрослый

Принимает здоровых добровольцев

Да

Метод выборки

Невероятностная выборка

Исследуемая популяция

The study population will consist of adults aged 18 years and older who are either healthy or undergoing intestinal ultrasound for inflammatory bowel disease screening, monitoring, or another clinical reason. Participants will be recruited through the IBD Centre of BC and other participating study sites. The study may include individuals with inflammatory bowel disease and healthy volunteers. The study aims to include a diverse participant population to support evaluation of artificial intelligence algorithm performance across different participant characteristics.

Описание

Inclusion Criteria:

  • Adults aged 18 years or older.
  • Individuals who are either healthy with no known finding of inflammatory bowel disease before the ultrasound examination or undergoing intestinal ultrasound for inflammatory bowel disease screening, monitoring, or another clinical reason.
  • Individuals who are able and willing to provide informed consent for the collection and use of de-identified study data.

Exclusion Criteria:

  • Individuals who do not meet the study demographic requirements.
  • Individuals unable or unwilling to provide informed consent.
  • Pregnant individuals.
  • Individuals with health conditions managed using drugs or medical-device intervention, or with unmanaged conditions or conditions requiring monitoring, that could affect study eligibility or the ultrasound assessment.
  • Individuals who have recently taken contrast-enhancing compounds.

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

Когорты и вмешательства

Группа / когорта
Вмешательство/лечение
Intestinal Ultrasound Participants
This cohort includes adults aged 18 years and older who are either healthy or undergoing intestinal ultrasound for inflammatory bowel disease screening, monitoring, or another clinical reason. Participants will undergo intestinal ultrasound as part of routine clinical care. With informed consent, de-identified ultrasound images and cine loops, along with limited associated information such as age, sex, self-reported race, and relevant scan-related details, will be collected for artificial intelligence algorithm development. No study drug, experimental treatment, or experimental device will be administered. The artificial intelligence algorithms will not be used to guide participant care or provide individual diagnostic results during the study.
Intestinal ultrasound images and cine loops will be collected from adults undergoing ultrasound as part of routine clinical care. Following informed consent, the images and cine loops will be de-identified and used for artificial intelligence algorithm development, training, tuning, and testing. The study does not assign participants to receive an intervention, and the ultrasound is not performed solely for research purposes. The artificial intelligence algorithms developed using the data will not be used to guide participant care or provide individual diagnostic results during the study.

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Artificial Intelligence-Generated Bowel Wall Thickness Measurement Agreement
Временное ограничение: Day 1, after completion of the intestinal ultrasound examination
Agreement between bowel wall thickness measurements generated by the artificial intelligence computer-vision algorithm and manual bowel wall thickness measurements performed by experienced sonographers using de-identified intestinal ultrasound images and cine loops. Agreement will be assessed using the pre-specified performance metric in the statistical analysis plan.
Day 1, after completion of the intestinal ultrasound examination

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Bowel Wall Layer Stratification Feasibility
Временное ограничение: Day 1, after completion of the intestinal ultrasound examination
Proportion of de-identified intestinal ultrasound images and cine loops for which the artificial intelligence algorithm generates an interpretable bowel wall layer stratification.
Day 1, after completion of the intestinal ultrasound examination
Luminal Diameter Measurement Feasibility
Временное ограничение: Day 1, after completion of the intestinal ultrasound examination
Proportion of de-identified intestinal ultrasound images and cine loops for which the artificial intelligence algorithm generates an interpretable luminal diameter measurement.
Day 1, after completion of the intestinal ultrasound examination
Bowel Wall Flow Assessment Feasibility
Временное ограничение: Day 1, after completion of the intestinal ultrasound examination
Proportion of de-identified intestinal ultrasound images and cine loops for which the artificial intelligence algorithm generates an interpretable bowel wall flow assessment.
Day 1, after completion of the intestinal ultrasound examination
Bowel Wall Scarring Assessment Feasibility
Временное ограничение: Day 1, after completion of the intestinal ultrasound examination
Proportion of de-identified intestinal ultrasound images and cine loops for which the artificial intelligence algorithm generates an interpretable bowel wall scarring assessment.
Day 1, after completion of the intestinal ultrasound examination
Gastrointestinal Motility Assessment Feasibility
Временное ограничение: Day 1, after completion of the intestinal ultrasound examination
Proportion of de-identified intestinal ultrasound images and cine loops for which the artificial intelligence algorithm generates an interpretable gastrointestinal motility assessment.
Day 1, after completion of the intestinal ultrasound examination
Mesenteric Fat Proliferation Assessment Feasibility
Временное ограничение: Day 1, after completion of the intestinal ultrasound examination
Proportion of de-identified intestinal ultrasound images and cine loops for which the artificial intelligence algorithm generates an interpretable assessment of mesenteric fat proliferation.
Day 1, after completion of the intestinal ultrasound examination
Proportion of Cine Loops Suitable for AI Development
Временное ограничение: At completion of dataset preparation
Percentage of collected de-identified cine loops that meet all pre-specified completeness, image-quality, and required-metadata criteria for artificial intelligence algorithm training, tuning, and testing.
At completion of dataset preparation

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Следователи

  • Главный следователь: Matthew J Smyth, MD, University of British Columbia, IBD Centre of BC

Публикации и полезные ссылки

Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Оцененный)

15 сентября 2026 г.

Первичное завершение (Оцененный)

1 февраля 2027 г.

Завершение исследования (Оцененный)

1 февраля 2027 г.

Даты регистрации исследования

Первый отправленный

2 сентября 2026 г.

Впервые представлено, что соответствует критериям контроля качества

9 сентября 2026 г.

Первый опубликованный (Действительный)

10 сентября 2026 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

10 сентября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

9 сентября 2026 г.

Последняя проверка

1 сентября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

НЕТ

Описание плана IPD

Individual participant-level data will not be made available to external researchers. The study will collect de-identified intestinal ultrasound images, cine loops, and limited associated information for use by Dova Health Intelligence Inc. in quality assessment, annotation, artificial intelligence algorithm training, tuning, testing, and related future algorithm-development activities described in the study protocol. Data will not be made publicly available or shared outside the authorized study collaborators.

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Нет

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться